Imugene (IUGNF) Price Target Reduced by 57.72% to 4.15

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Oct 29 2025

0mins

Source: NASDAQ.COM

Price Target Revision: The average one-year price target for Imugene (OTCPK:IUGNF) has been revised down to $4.15 per share, a decrease of 57.72% from the previous estimate of $9.81.
Analyst Targets Range: Current analyst targets for Imugene range from a low of $0.47 to a high of $8.06 per share, representing a significant potential increase of 10,271.35% from the latest closing price of $0.04.
Institutional Holdings: There are 16 funds reporting positions in Imugene, with total shares owned by institutions decreasing by 61.12% over the last three months to 85,821K shares, while the average portfolio weight dedicated to IUGNF increased by 57.42%.
Shareholder Changes: Major shareholders like Vanguard and Schwab have significantly reduced their holdings in Imugene, with some decreasing their portfolio allocations by over 60% in the last quarter.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.